Description
Glycolaldehyde-pyridine (GA-pyridine) is an advanced glycation end product (AGE).{15062,49055} It is formed via the reaction of GA, a product of myeloperoxidase activity, with lysine and can therefore serve as an antigenic marker of protein modification resulting from myeloperoxidase activity.{15062} GA-pyridine has been detected in the tubular epithelial cells, renal vasculature, and glomerular epithelium of both healthy and diseased human kidneys, and accumulates in the glomerular mesangium of patients with renal diseases, including diabetic nephropathy, Wegener’s granulomatosis, mesangial proliferative glomerulonephritis, and focal glomerular sclerosis.{49055} GA-pyridine also accumulates in the cytoplasm of foam cells and extracellularly in the atheromatous core of human atherosclerotic lesions.{15062} Cayman’s AGE (GA-Pyridine Specific) Monoclonal Antibody (Clone 3G2) can be used for Western blot and ELISA applications. This antibody recognizes GA AGE-modified proteins.
Synonyms: Advanced Glycation End Products (Glycolaldehyde-pyridine)
Immunogen: GA-pyridine-BSA
Formulation: 100 µg of protein G-purified monoclonal antibody
Isotype: IgG2b
Applications: ELISA, WB
Origin:
Stability: 365 days
Application|ELISA||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Kidney & Renal Disease|Diabetic Nephropathy
